Control of mesothelin-expressing ovarian cancer using adoptive transfer of mesothelin peptide-specific CD8+ T cells

Chien-Fu Hung, Y. C. Tsai, L. He, Tzyy Choou Wu

Research output: Contribution to journalArticle

Abstract

Cancer immunotherapy targeting mesothelin represents a potentially plausible approach for the control of ovarian cancer as most ovarian cancers express high levels of mesothelin. In the current study, we created a mesothelin-positive luciferase-expressing ovarian cancer model, MOSEC/luc. This luciferase-expressing tumor model allowed us to quantitate tumor distribution and tumor load in tumor-challenged mice using a non-invasive bioluminescence imaging system. In addition, we identified an H-2Db-restricted mesothelin peptide-specific cytotoxic T-lymphocyte (CTL) epitope (amino acid (aa) 406-414) that was endogenously processed and presented by MOSEC/luc tumor cells. We showed that adoptive transfer of mesothelin peptide (aa406-414)-specific CD8+ T cells led to the control of MOSEC/luc tumor cells. The MOSEC/luc tumor model and the newly identified H-2Db -restricted murine mesothelin-specific CTL epitope (aa406-414) will be very useful for the development of immunotherapy for ovarian cancer as well as for the development of quantitative CD8+ T cell-mediated immunological assays.

Original languageEnglish (US)
Pages (from-to)921-929
Number of pages9
JournalGene Therapy
Volume14
Issue number12
DOIs
StatePublished - Jun 2007

Fingerprint

Adoptive Transfer
Ovarian Neoplasms
T-Lymphocytes
Peptides
Neoplasms
T-Lymphocyte Epitopes
Cytotoxic T-Lymphocytes
Luciferases
Immunotherapy
mesothelin
Tumor Burden
Amino Acids

ASJC Scopus subject areas

  • Genetics

Cite this

Control of mesothelin-expressing ovarian cancer using adoptive transfer of mesothelin peptide-specific CD8+ T cells. / Hung, Chien-Fu; Tsai, Y. C.; He, L.; Wu, Tzyy Choou.

In: Gene Therapy, Vol. 14, No. 12, 06.2007, p. 921-929.

Research output: Contribution to journalArticle

@article{421b7a00bf76432393d2bae21c36f876,
title = "Control of mesothelin-expressing ovarian cancer using adoptive transfer of mesothelin peptide-specific CD8+ T cells",
abstract = "Cancer immunotherapy targeting mesothelin represents a potentially plausible approach for the control of ovarian cancer as most ovarian cancers express high levels of mesothelin. In the current study, we created a mesothelin-positive luciferase-expressing ovarian cancer model, MOSEC/luc. This luciferase-expressing tumor model allowed us to quantitate tumor distribution and tumor load in tumor-challenged mice using a non-invasive bioluminescence imaging system. In addition, we identified an H-2Db-restricted mesothelin peptide-specific cytotoxic T-lymphocyte (CTL) epitope (amino acid (aa) 406-414) that was endogenously processed and presented by MOSEC/luc tumor cells. We showed that adoptive transfer of mesothelin peptide (aa406-414)-specific CD8+ T cells led to the control of MOSEC/luc tumor cells. The MOSEC/luc tumor model and the newly identified H-2Db -restricted murine mesothelin-specific CTL epitope (aa406-414) will be very useful for the development of immunotherapy for ovarian cancer as well as for the development of quantitative CD8+ T cell-mediated immunological assays.",
author = "Chien-Fu Hung and Tsai, {Y. C.} and L. He and Wu, {Tzyy Choou}",
year = "2007",
month = "6",
doi = "10.1038/sj.gt.3302913",
language = "English (US)",
volume = "14",
pages = "921--929",
journal = "Gene Therapy",
issn = "0969-7128",
publisher = "Nature Publishing Group",
number = "12",

}

TY - JOUR

T1 - Control of mesothelin-expressing ovarian cancer using adoptive transfer of mesothelin peptide-specific CD8+ T cells

AU - Hung, Chien-Fu

AU - Tsai, Y. C.

AU - He, L.

AU - Wu, Tzyy Choou

PY - 2007/6

Y1 - 2007/6

N2 - Cancer immunotherapy targeting mesothelin represents a potentially plausible approach for the control of ovarian cancer as most ovarian cancers express high levels of mesothelin. In the current study, we created a mesothelin-positive luciferase-expressing ovarian cancer model, MOSEC/luc. This luciferase-expressing tumor model allowed us to quantitate tumor distribution and tumor load in tumor-challenged mice using a non-invasive bioluminescence imaging system. In addition, we identified an H-2Db-restricted mesothelin peptide-specific cytotoxic T-lymphocyte (CTL) epitope (amino acid (aa) 406-414) that was endogenously processed and presented by MOSEC/luc tumor cells. We showed that adoptive transfer of mesothelin peptide (aa406-414)-specific CD8+ T cells led to the control of MOSEC/luc tumor cells. The MOSEC/luc tumor model and the newly identified H-2Db -restricted murine mesothelin-specific CTL epitope (aa406-414) will be very useful for the development of immunotherapy for ovarian cancer as well as for the development of quantitative CD8+ T cell-mediated immunological assays.

AB - Cancer immunotherapy targeting mesothelin represents a potentially plausible approach for the control of ovarian cancer as most ovarian cancers express high levels of mesothelin. In the current study, we created a mesothelin-positive luciferase-expressing ovarian cancer model, MOSEC/luc. This luciferase-expressing tumor model allowed us to quantitate tumor distribution and tumor load in tumor-challenged mice using a non-invasive bioluminescence imaging system. In addition, we identified an H-2Db-restricted mesothelin peptide-specific cytotoxic T-lymphocyte (CTL) epitope (amino acid (aa) 406-414) that was endogenously processed and presented by MOSEC/luc tumor cells. We showed that adoptive transfer of mesothelin peptide (aa406-414)-specific CD8+ T cells led to the control of MOSEC/luc tumor cells. The MOSEC/luc tumor model and the newly identified H-2Db -restricted murine mesothelin-specific CTL epitope (aa406-414) will be very useful for the development of immunotherapy for ovarian cancer as well as for the development of quantitative CD8+ T cell-mediated immunological assays.

UR - http://www.scopus.com/inward/record.url?scp=34249896459&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34249896459&partnerID=8YFLogxK

U2 - 10.1038/sj.gt.3302913

DO - 10.1038/sj.gt.3302913

M3 - Article

VL - 14

SP - 921

EP - 929

JO - Gene Therapy

JF - Gene Therapy

SN - 0969-7128

IS - 12

ER -